Traduction de «connection with its recognition » (Néerlandais → Français) :

Mdeon follows the guidelines authorised in connection with its recognition and ensures strict compliance with the legal requirements (article 10 of the law of 25 March 1964 on medicines).
Mdeon follows the guidelines authorised in connection with its recognition and ensures strict compliance with the legal requirements (article 10 of the law of 25 March 1964 on medicines).

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

NPC has been cooperating with parallel civil and criminal investigations by the EDPA into allegations of potential off-label marketing and promotion of the epilepsy therapy Trileptal as well as certain payments made to healthcare providers in connection with this medicine. Earlier this year, NPC entered into a plea agreement with the EDPA, which is contingent on court approval, to resolve criminal allegations.
NPC coopère aux investigations civiles et criminelles que l’EDPA mène en parallèle au sujet d’accusations de promotion de Trileptal, un traitement contre l’épilepsie, pour des indications pour lesquelles ce produit n’a pas été autorisé, et de certains paiements à des prestataires de soins de santé en lien avec ce médicament.

Novartis is also cooperating with an inquiry by the EDPA regarding similar allegations of potential off-label marketing and promotion and payments to healthcare providers in connection with five other products: Diovan, Exforge, Sandostatin, Tekturna and Zelnorm.
Novartis coopère également avec l’EPDA dans le cadre d’une enquête concernant des accusations similaires en relation avec cinq autres produits: Diovan, Exforge, Sandostatine, Tekturna et Zelnorm.

Novartis is cooperating with parallel civil and criminal investigations of the US Attorney’s Office into allegations of potential off-label marketing and promotion of the epilepsy therapy Trileptal as well as certain payments made to healthcare providers in connection with this medicine.
Novartis coopère aux investigations civiles et criminelles que ce bureau mène en parallèle au sujet d’accusations de promotion de Trileptal, un traitement contre l’épilepsie, pour des indications pour lesquelles ce produit n’a pas été autorisé, et de certains paiements à des prestataires de soins de santé en lien avec ce médicament.

Central to this endeavour are the six key factors which represent the FAMHP’s vision and ambition: ●● Recognition at national, European and international level ●● Developing partnerships with the healthcare
Central to this endeavour are the six key factors which represent the FAMHP’s vision and ambition: ●● Recognition at national, European and international level ●● Developing partnerships with the healthcare

Unit II Unit II is responsible for: ●● The recognition of industrial pharmacists ●● The granting of authorisations for the manufacture, import, export, wholesale, distribution of medicines ●● Dealing with quality problems (RAS – Rapid
Unit II Unit II is responsible for: ●● The recognition of industrial pharmacists ●● The granting of authorisations for the manufacture, import, export, wholesale, distribution of medicines ●● Dealing with quality problems (RAS – Rapid

In this context, the European Union also has mutual recognition agreements with Australia, New Zealand, Canada, Japan and Switzerland.
In this context, the European Union also has mutual recognition agreements with Australia, New Zealand, Canada, Japan and Switzerland.

The Precursors unit also took part in the international Cristal Flow action in connection with the PRISM project in 2007.
The Precursors unit also took part in the international Cristal Flow action in connection with the PRISM project in 2007.

However, such medicines do have to meet a number of quality and efficacy conditions, which are investigated in connection with the ED.
However, such medicines do have to meet a number of quality and efficacy conditions, which are investigated in connection with the ED.